secwatch.observer — SEC 8-K summary
======================================

Issuer:     Axsome Therapeutics, Inc. (AXSM)
CIK:        0001579428
Form:       8-K
Filed at:   2025-11-03T23:59:59+00:00
Accession:  0001193125-25-261651
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Axsome Q3 2025 net product revenue $171M, up 63% YoY; submits sNDA for AXS-05 in Alzheimer's agitation
--------------------------------------------------------------------------------

- Total net product revenue $171.0M (63% YoY growth); AUVELITY $136.1M (+69%), SUNOSI $32.8M (+35%), SYMBRAVO $2.1M (first full quarter).
- Net loss narrowed to $47.2M ($0.94/share) from $64.6M ($1.34/share) in Q3 2024; cash $325.3M.
- Submitted sNDA for AXS-05 in Alzheimer's disease agitation (FDA Breakthrough Therapy); plans NDA submission for AXS-12 in narcolepsy in Q4 2025.
- Pipeline: Phase 3 trials to initiate in Q4 2025 for AXS-05 (smoking cessation), solriamfetol (pediatric ADHD, MDD+EDS), and AXS-14 (fibromyalgia).
- AUVELITY prescriptions ~209k in Q3 (+46% YoY); contracted with third large GPO; payer coverage ~85%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1579428/000119312525261651/0001193125-25-261651-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1579428/000119312525261651/axsm-20251103.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-261651

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer